Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $82.00 price target on the stock. APLS has been the topic of several other research reports. Wells Fargo & Company decreased their target price on […]

Related Keywords

Virginia ,United States ,Raymond James ,Alec Machiels ,Robertw Baird ,Karen Lewis ,Apellis Pharmaceuticals Trading ,Institutional Trading Of Apellis Pharmaceuticals ,Apellis Pharmaceuticals ,Citigroup ,Perceptive Advisors ,Wells Fargo Company ,Jpmorgan Chase Co ,Apellis Pharmaceuticals Inc ,Analyst Recommendations For Apellis Pharmaceuticals ,Apellis Pharmaceuticals Company Profile ,Legato Capital Management ,Castleark Management ,News Ratings For Apellis Pharmaceuticals Daily ,Free Report ,Moderate Buy ,Get Free Report ,Director Alec Machiels ,Retirement Systems ,Capital Management ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Reiterated Rating ,Hc Wainwright ,